Spinraza

E24879

Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.

All labels observed (3)

Label Occurrences
nusinersen 5
Spinraza canonical 4
SMN2 1

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf antisense oligonucleotide
biologic medicinal product
medication
orphan drug
prescription drug
approvedBy European Medicines Agency
U.S. Food and Drug Administration
developedBy Biogen
Ionis Pharmaceuticals
hasActiveIngredient nusinersen
linked to: Spinraza
hasAdministrationSite cerebrospinal fluid
hasATCCode M09AX07
hasBrandOwner Biogen
hasCommonAdverseEffect back pain
constipation
headache
nausea
respiratory infection
hasDosageForm solution for injection
hasGenericName nusinersen
linked to: Spinraza
hasInternationalNonproprietaryName nusinersen
linked to: Spinraza
hasLoadingDoseRegimen four loading doses over approximately two months
hasMaintenanceDoseRegimen one dose every four months
hasPregnancyCategory not assigned; use only if potential benefit justifies potential risk
hasSeriousAdverseEffect coagulation abnormalities
renal toxicity
thrombocytopenia
hasTherapeuticArea neurology
rare diseases
increasesProductionOf SMN protein
survival motor neuron protein
indicatedFor adult patients with spinal muscular atrophy
pediatric patients with spinal muscular atrophy
isAdministeredBy healthcare professional
isFirstDrugApprovedFor spinal muscular atrophy
isUsedAs disease-modifying therapy for spinal muscular atrophy
legalStatusInEuropeanUnion prescription only
legalStatusInUnitedStates prescription only
mechanismOfAction antisense oligonucleotide that modulates SMN2 pre-mRNA splicing
modifiesGeneExpression SMN2
regulatoryApprovalYear 2016
requiresMonitoringOf coagulation parameters
platelet count
renal function
routeOfAdministration intrathecal
lumbar puncture
targetsGene SMN2
linked to: Spinraza
treats 5q spinal muscular atrophy
spinal muscular atrophy

How these facts were elicited

Referenced by (10)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen hasProduct Spinraza
Biogen hasNotableDrug Spinraza
Spinraza hasGenericName nusinersen
linked to: Spinraza
Spinraza hasInternationalNonproprietaryName nusinersen
linked to: Spinraza
Spinraza hasActiveIngredient nusinersen
linked to: Spinraza
Spinraza targetsGene SMN2
linked to: Spinraza
spinal muscular atrophy treatedBy nusinersen
linked to: Spinraza
SMN2 targetOfDrug nusinersen
linked to: Spinraza